中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
27期
108-110
,共3页
慢性乙型肝炎%拉米夫定%失效%恩替卡韦%疗效
慢性乙型肝炎%拉米伕定%失效%恩替卡韋%療效
만성을형간염%랍미부정%실효%은체잡위%료효
Chronic hepatitis b%Lamivudine%Failure%Entecavir%The curative effect
目的 展开对恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究. 方法 将随机选取该院住院部自2011年1月-2014年12月期间收治的80例慢性乙型肝炎患者纳入临床研究,随机分为对照组,观察组.对照组以安慰剂干预,观察组以恩替卡韦干预,就临床效果进行对比. 结果 治疗前两组乙肝病毒基因检出值对比差异无统计学意义(P>0.05);接受治疗2、4、8周,观察组乙肝病毒基因检出值均明显低于对照组,对比差异有统计学意义(P<0.05). 接受8周治疗后,观察组乙肝病毒基因检出转阴率为75.00%(30/40),明显高于对照组 7.50%(3/40),对比差异有统计学意义(P<0.05). 两组患者不良事件对比差异无统计学意义(P>0.05). 结论 针对拉米夫定治疗失效的慢性乙型肝炎患者,应用恩替卡韦替代治疗效果确切,对降低乙肝病毒基因水平,提高乙肝病毒基因转阴率方面效果确切,且用药安全,值得推广.
目的 展開對恩替卡韋治療拉米伕定失效的慢性乙型肝炎患者多中心隨機雙盲對照臨床研究. 方法 將隨機選取該院住院部自2011年1月-2014年12月期間收治的80例慢性乙型肝炎患者納入臨床研究,隨機分為對照組,觀察組.對照組以安慰劑榦預,觀察組以恩替卡韋榦預,就臨床效果進行對比. 結果 治療前兩組乙肝病毒基因檢齣值對比差異無統計學意義(P>0.05);接受治療2、4、8週,觀察組乙肝病毒基因檢齣值均明顯低于對照組,對比差異有統計學意義(P<0.05). 接受8週治療後,觀察組乙肝病毒基因檢齣轉陰率為75.00%(30/40),明顯高于對照組 7.50%(3/40),對比差異有統計學意義(P<0.05). 兩組患者不良事件對比差異無統計學意義(P>0.05). 結論 針對拉米伕定治療失效的慢性乙型肝炎患者,應用恩替卡韋替代治療效果確切,對降低乙肝病毒基因水平,提高乙肝病毒基因轉陰率方麵效果確切,且用藥安全,值得推廣.
목적 전개대은체잡위치료랍미부정실효적만성을형간염환자다중심수궤쌍맹대조림상연구. 방법 장수궤선취해원주원부자2011년1월-2014년12월기간수치적80례만성을형간염환자납입림상연구,수궤분위대조조,관찰조.대조조이안위제간예,관찰조이은체잡위간예,취림상효과진행대비. 결과 치료전량조을간병독기인검출치대비차이무통계학의의(P>0.05);접수치료2、4、8주,관찰조을간병독기인검출치균명현저우대조조,대비차이유통계학의의(P<0.05). 접수8주치료후,관찰조을간병독기인검출전음솔위75.00%(30/40),명현고우대조조 7.50%(3/40),대비차이유통계학의의(P<0.05). 량조환자불량사건대비차이무통계학의의(P>0.05). 결론 침대랍미부정치료실효적만성을형간염환자,응용은체잡위체대치료효과학절,대강저을간병독기인수평,제고을간병독기인전음솔방면효과학절,차용약안전,치득추엄.
Objective Lamivudine on entecavir treatment failure in patients with chronic hepatitis b multicenter randomized dou-ble-blind controlled clinical studies. Methods Our hospital in-patient department since January 2011 to December 2014 admitted during the period of 80 cases of chronic hepatitis b patients in clinical research, were randomly divided into control group and treatment group. The control group with placebo intervention, observation group with entecavir intervention. Comparing clinical ef-fect. Results The two groups before treatment of hepatitis b virus gene detection value contrast has no obvious difference, P> 0.05, no statistically significant.Treatment 2 weeks, 4 weeks, 8 weeks, hepatitis b virus gene detection value of observation group were significantly lower than the control group, there was a significant difference compared,P<0.05, with statistical significance. After 8 weeks treatment, observation group turn the hepatitis b virus gene detection rate was 75.00% (30/40), significantly higher than the control group 7.50% (3/40), contrast have significant difference, P< 0.05, with statistical significance. No difference between the two groups of adverse events in patients with contrast,P > 0.05, is not statistically significant. Conclusion Lamivudine treatment failure in patients with chronic hepatitis b, application of entecavir replacement therapy effect is exact, to reduce the hepatitis b virus gene level, increase the rate of hepatitis b virus genes turn on effect is exact, and drug safety, is worth promoting.
